Rivera PR, Suárez NED, Flores MR, Guzmán CJ, d’Hyver DDJ W

Idioma: Español
Referencias bibliográficas: 28
Paginas: 245-248
Archivo PDF: 84.31 Kb.

FRAGMENTO

La trimetazidina es un fármaco que se ha utilizado desde finales de la década de los sesenta, sin embargo tiene poco que se sabe su mecanismo de acción; este medicamento actúa a nivel de la mitocondria disminuyendo la oxidación de los ácidos grasos. En la actualidad tiene una gran importancia el conocer a la trimetazidina por las nuevas indicaciones que están surgiendo; la difusión de este medicamento es básicamente en los países donde se encuentra disponible: Europa, Asia y algunos países de América Latina.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Stanley WC. Cardiac energetics during ischemia and the rationale for metabolic interventions. Coron Artery Dis 2001; 12(Suppl 1): S3-7.

2. Jackson PJ, Brownsill RD, Taylor AR. Identification of trimetazidine metabolites in human urine and plasma. Xenobiotica 1996; 26(2): 221-8.

3. Barré J, Ledudal P, Oosterhuis et al. Pharmacokinetic profile of a modified release formulation of trimetazidine (TMZ MR 35 mg) in the elderly and patients with renal failure. Biopharmaceutics & Drug Disposition 2003; 24: 159-64.

4. Kantor PF, Lucien A, Kozak R, Lopaschuk GD. The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase. Circ Res 2000; 86: 580-8.

5. Mody FV, Singh B, Mohiuddin I et al. Trimetazidine-induced enhancement of myocardial glucose utilization in normal and ischemic myocardial tissue: an evaluation by positron emission tomography. Am J Cardiol 1998; 82: 42K-49K.

6. El Banani H, Bernard M, Baetz D et al. Changes in intracellular sodium and pH during ischaemia-reperfusion are attenuated by trimetazidine; comparison of low- and zero-flow ischaemia. Cardiovasc Res 2000; 44: 688-696.

7. Sentex E, Lucien A, Grynberg A et al. Influence of trimetazidine on the synthesis of complex lipids in the heart and other target organs. Fund Clin Pharmacol 2001; 15: 255-264.

8. Belardinelli R, Solenghi M, Volpe L. Trimetazidine improves endothelial dysfunction in chronic heart failure: an antioxidant effect. European Heart Journal 2007; 28(9): 1102-8.

9. Gibbons RJ, Abrams J, Chatterjee K, Daley J, Deedwania PC, Douglas JS et al. ACC/AHA 2002 guideline update for the management of patients with chronic stable angina: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.

10. Ciapponi A, Pizarro R, Harrison J. Trimetazidine for stable angina. Cochrane Database of Systematic Reviews (4):CD003614, 2005.

11. Mehrotra, TN, Bassadone, ET. Trimetazidine in the treatment of angina pectoris. British Journal of Clinical Practice 1967; 21(11): 553-4.

12. Manchanda SC. Treatment of stable angina with low dose diltiazem in combination with the metabolic agent trimetazidine. International Journal of Cardiology 2003; 88: 83-99.

13. Makolkin VI, Osadchiy KK. Trimetazidine modified release in the treatment of stable angina: TRIUMPH Study Trimetazidine MR in patients with stable angina: Unique metabolic PatH. Clinical Drug Investigation 2004; 24(12): 731-38.

14. Papadopoulus CL, Kanonidis IE, Kotridis PS, Papayannis IL. The effects of trimetazidine on reperfusion arrhythmias in acute myocardial infarction. International Journal of Cardiology 1996; 55(2): 137-42.

15. Labrou A, Giannoglou G, Zioutas D, Fragakis N, Katsaris G, Louridas G. Trimetazidine administration minimizes myocardial damage and improves left ventricular function after percutaneous coronary intervention. American Journal of Cardiovascular Drugs 2007; 7: 143-50.

16. Bonello L, Sbragia P, Amabile N. Protective effect of an acute oral loading dose of trimetazidine on myocardial injury following percutaneous coronary intervention. Heart 2007; 93: 703-707.

17. Fragasso G, Palloshi A, Puccetti P. A Randomized clinical trial of trimetazidine, a partial free fatty acid oxidation inhibitor, in patients with heart failure. J Am Coll Cardiol 2006; 48: 992-8.

18. Sisakian H, Torgomyan A, Barkhudaryan A. The effect of trimetazidine on left ventricular systolic function and physical tolerance in patients with ischaemic cardiopathy. Acta Cardiologica 2007; 62(5): 493-9.

19. Iskesen I, Saribulbul O, Cerrahoglu M et al. Trimetazidine reduces oxidative stress in cardiac surgery. Circulation Journal 2006; 70(9): 1169-73.

20. Coyas A. The efficacy of trimetazidine in cochleovestibular disorders of ischemic origin. A crossover control versus placebo trial. Ann Oto-laryngol Chir Cervico-fac 1990; 107(Suppl 1): 82-7.

21. Pech A. A multicenter double blind versus placebos study of trimetazidine in tinnitus. A clinical approach to tinnitus. Ann Oto-laryngol Chir Cervico-fac 1990; 107(Suppl 1): 66-7.

22. Dayanithi G, Desmadryl G, Travo C. Trimetazidine modulates AMPA/kinate receptor in rat ganglio neurons. European Journal of Pharmacology 2007; 574(1): 8-14.

23. Grekas D, Dioudis C, Papageorgiou G, Iliadis S. Lipid peroxidation after acute renal ischemia and reperfusion in rats: the effect of trimetazidine. Renal Failure 1996; 18(4): 545-52.

24. Onbasili OA, Yeniceriglu Y, Agaoglu P. Trimetazidine in the prevention of contrast-induced nephropathy after coronary procedures. Heart 2007; 93: 698-702.

25. Bayram E, Atala C, Kocatürk H, Yücel O. Effects of trimetazidine on lipid peroxidation, antioxidant enzyme activities and plasma brain natriuretic peptide levels in patients with chronic cor pulmonale. The Journal of International Medical Research 2005; 33: 612–19.

26. Kaya Y, Coskun T, Aral E, Erkasap N. The effect of trimetazidine on liver regeneration after hepatectomy under hepatic blood inflow occlusion. Hepatogastroenterology 2003; 50(51): 651-5.

27. Nowak P, Zagzi T, Konecki J. Trimetazidine increases [3H]glucose uptake in rat brain. Pharmacological Reports 2006; 58: 559-61.

28. Masso JF, Marti I, Carrera N et al. Trimetazidine induces parkinsonism, gait disorders and tremor. Therapie 2005; 60(4): 419-22.